Maryland’s Prescription Drug Affordability Board approved upper payment limits for two prescription drugs, set to take effect Jan. 1. The policy applies to what state and local government purchasers pay—not pharmacy-counter prices for patients—marking Maryland as one of the first states to implement UPLs despite court challenges and criticism elsewhere. Industry groups and analysts argue the pricing mechanism may not translate into lower out-of-pocket costs for patients and could reduce access if commercial incentives shift. The board’s structure is designed to target institutional reimbursement levels, but the debate centers on whether that lever actually improves affordability. For biotech and pharma, this is a live signal on payer-side pricing pressure and contract negotiation dynamics in government-linked channels.
Get the Daily Brief